IL284298A - Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases - Google Patents
Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseasesInfo
- Publication number
- IL284298A IL284298A IL284298A IL28429821A IL284298A IL 284298 A IL284298 A IL 284298A IL 284298 A IL284298 A IL 284298A IL 28429821 A IL28429821 A IL 28429821A IL 284298 A IL284298 A IL 284298A
- Authority
- IL
- Israel
- Prior art keywords
- prevention
- compounds
- treatment
- active substances
- therapeutically active
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/235,543 US10752593B2 (en) | 2018-12-28 | 2018-12-28 | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| PCT/US2019/068759 WO2020140043A1 (en) | 2018-12-28 | 2019-12-27 | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL284298A true IL284298A (en) | 2021-08-31 |
Family
ID=69188012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284298A IL284298A (en) | 2018-12-28 | 2021-06-22 | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10752593B2 (https=) |
| EP (1) | EP3902606A1 (https=) |
| JP (1) | JP2022516086A (https=) |
| KR (1) | KR20210110849A (https=) |
| CN (1) | CN113301958A (https=) |
| AU (1) | AU2019414950A1 (https=) |
| BR (1) | BR112021011599A2 (https=) |
| CA (1) | CA3125278A1 (https=) |
| CL (1) | CL2021001725A1 (https=) |
| EA (1) | EA202191057A1 (https=) |
| IL (1) | IL284298A (https=) |
| MX (1) | MX2021007813A (https=) |
| PH (1) | PH12021551092A1 (https=) |
| SG (1) | SG11202104958UA (https=) |
| WO (1) | WO2020140043A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010758A1 (en) | 1996-09-13 | 1998-03-19 | The Regents Of The University Of California | Methods for treatment of retinal diseases |
| CA2216439A1 (en) | 1996-09-25 | 1998-03-25 | Derek Van Der Kooy | Pharmaceuticals containing retinal stem cells |
| WO2001039792A2 (en) | 1999-12-03 | 2001-06-07 | Alcon Universal Ltd. | The use of caspase 9 inhibitors to treat ocular neural pathology |
| AU2008335709A1 (en) | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
| US9018202B2 (en) | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| US20130046003A1 (en) | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| WO2013029338A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| WO2014079850A1 (en) | 2012-11-23 | 2014-05-30 | F. Hoffmann-La Roche Ag | Substituted heterocyclic derivatives |
| DE102013110714A1 (de) | 2013-09-27 | 2015-04-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung |
| BR112017009584A2 (pt) | 2014-11-07 | 2017-12-26 | Nacuity Pharmaceuticals Inc | tratamento de retinite pigmentosa com n-acetilcisteína amida |
-
2018
- 2018-12-28 US US16/235,543 patent/US10752593B2/en not_active Expired - Fee Related
-
2019
- 2019-12-27 MX MX2021007813A patent/MX2021007813A/es unknown
- 2019-12-27 EA EA202191057A patent/EA202191057A1/ru unknown
- 2019-12-27 WO PCT/US2019/068759 patent/WO2020140043A1/en not_active Ceased
- 2019-12-27 CA CA3125278A patent/CA3125278A1/en active Pending
- 2019-12-27 AU AU2019414950A patent/AU2019414950A1/en not_active Abandoned
- 2019-12-27 EP EP19842557.1A patent/EP3902606A1/en not_active Withdrawn
- 2019-12-27 KR KR1020217023914A patent/KR20210110849A/ko not_active Ceased
- 2019-12-27 BR BR112021011599-4A patent/BR112021011599A2/pt not_active Application Discontinuation
- 2019-12-27 CN CN201980085675.1A patent/CN113301958A/zh active Pending
- 2019-12-27 JP JP2021537220A patent/JP2022516086A/ja not_active Withdrawn
- 2019-12-27 SG SG11202104958UA patent/SG11202104958UA/en unknown
-
2021
- 2021-05-11 PH PH12021551092A patent/PH12021551092A1/en unknown
- 2021-06-22 IL IL284298A patent/IL284298A/en unknown
- 2021-06-25 CL CL2021001725A patent/CL2021001725A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3125278A1 (en) | 2020-07-02 |
| EA202191057A1 (ru) | 2021-10-07 |
| KR20210110849A (ko) | 2021-09-09 |
| SG11202104958UA (en) | 2021-07-29 |
| AU2019414950A1 (en) | 2021-06-03 |
| WO2020140043A1 (en) | 2020-07-02 |
| EP3902606A1 (en) | 2021-11-03 |
| MX2021007813A (es) | 2021-10-01 |
| US20200207719A1 (en) | 2020-07-02 |
| JP2022516086A (ja) | 2022-02-24 |
| BR112021011599A2 (pt) | 2021-08-31 |
| CL2021001725A1 (es) | 2021-12-17 |
| PH12021551092A1 (en) | 2021-12-06 |
| US10752593B2 (en) | 2020-08-25 |
| CN113301958A (zh) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| WO2015187998A3 (en) | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy | |
| SMT202400271T1 (it) | Composizione farmaceutica per l’uso nel trattamento o nella prevenzione di una patologia correlata a c5 | |
| IL272097A (en) | Compounds for the prevention and treatment of medical disorders and their uses | |
| ES3064839T3 (en) | Combination of cannabidiol and buprenorphine and its use for the treatment of chronic pain | |
| IL282904A (en) | Therapeutic microbiota for the treatment and/or prevention of dysbiosis | |
| IL281585B (en) | Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use | |
| IL289758B2 (en) | Proportin inhibitors for use in the prevention and treatment of kidney injury | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| GB201519557D0 (en) | Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions | |
| IL284298A (en) | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases | |
| IL282718A (en) | Compounds for use in the treatment or prevention of pain, inflammation and/or autoimmune diseases | |
| EP4017496A4 (en) | FORMULATIONS FOR THE PREVENTION AND/OR TREATMENT OF PERIPHERAL NEUROPATHY AND ITS ASSOCIATED DISEASES | |
| HUE066609T2 (hu) | Adagolási forma betegség kezelésében vagy megelõzésében történõ alkalmazásra | |
| PL3937948T3 (pl) | Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu chorób nerwowo-mięśniowych | |
| PT4081507T (pt) | Compostos químicos direcionados para o olho e a sua utilização no tratamento de doenças oculares | |
| EP3458031A4 (en) | TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF CELECOXIB AND THEIR USE IN THE TREATMENT OF CELCOXIB-SENSITIVE DISEASES AND CONDITIONS | |
| PL3813843T3 (pl) | Kompozycja do stosowania w zapobieganiu i/lub leczeniu chorób układu kostno-stawowego | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
| GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
| SG11202101788VA (en) | Agent for the treatment of skin wounds or burns | |
| HK40036525A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |